ABSTRACT Rationale: Severe alpha 1-antitrypsin deficiency is an autosomal recessive genetic condition associated with an increased, but variable, risk for chronic obstructive pulmonary disease (COPD). Objective: To assess the impact of chronic bronchitis, pneumonia, asthma, and sex on the development of COPD in individuals with severe alpha 1-antitrypsin deficiency. Methods: The Alpha 1-Antitrypsin Genetic Modifier Study is a multi-center familybased cohort study designed to study the genetic and epidemiological determinants of COPD in alpha 1-antitrypsin deficiency. 378 individuals (age range: 33-80), confirmed to be homozygous for the SERPINA1 Z mutation, were included in the analyses.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a complex disease characterized by variable susceptibility; this variability is likely determined by genes interacting with other predisposing host factors and environmental exposures. Homozygosity for the Z mutation in the SERPINA1 gene is an autosomal recessive genetic risk factor for COPD due to alpha 1-antitrypsin deficiency. Although at high genetic risk, individuals with two severe deficiency alleles (e.g. PI ZZ) have marked variability in the extent of COPD, consistent with the hypothesis that other factors may be relevant to the development of obstructive lung disease.
Alpha 1-antitrypsin (AAT) is the main plasma inhibitor of neutrophil elastase, and the inherited deficiency of AAT has been clearly proven to be associated with the development of early-onset emphysema 1 . In the presence of AAT deficiency, cigarette smoking is an important contributor to accelerated lung function decline, and the extent of lung injury is usually disproportionate to the amount smoked. The Z allele of the AAT gene is associated with a marked decrement in serum AAT levels, but studies of PI Z individuals have demonstrated substantial variability of lung disease in smokers. In individuals who have never smoked cigarettes, there is also wide variability for the development of airflow obstruction 2, 3 . Factors such as asthma, pneumonia, other childhood respiratory illnesses [4] [5] [6] , chronic bronchitis, differential impact of gender/sex biology, and modifier genes all may have a role in the development of lung disease in AAT deficient individuals.
The vast majority of individuals with severe alpha 1-antitrypsin deficiency are identified after being diagnosed with lung or liver disease; based on gene frequency estimates, most PI ZZ subjects remain unidentified. The ascertainment scheme involved in identifying most PI ZZ subjects with existing liver or lung disease has biased insight into the natural history of PI ZZ individuals. As part of our AAT Genetic Modifier Study, we ascertained individuals based upon the presence of two Z alleles (irrespective of lung/liver disease) and investigated characteristics that may be associated with obstructive lung disease in PI ZZ siblings and other relatives. Focusing on predictive characteristics in non-index PI ZZ subjects partially avoids the issues of ascertainment bias and likely provides a more accurate view of natural history of obstructive lung disease in PI ZZ individuals. However, since non-index PI ZZ subjects are typically (but not always) relatives of individuals with lung and/or liver disease, the findings may not be completely generalizable to the entire PI ZZ population.
We have assembled a large cohort of PI ZZ index and non-index subjects in families who have undergone standardized phenotyping with a questionnaire and spirometry. The careful phenotyping and inclusion of index and non-index individuals provides a unique opportunity to test the hypothesis that ascertainment, gender, asthma, chronic bronchitis and pneumonia significantly and independently are associated with airflow obstruction in PI ZZ subjects.
METHODS

Study sites and participants
The AAT Genetic Modifier Study is a multi-center study in collaboration with the Alpha-1 Foundation, designed to study the genetic epidemiology of lung disease in PI ZZ individuals. The study protocol was reviewed by the individual Institutional Review Boards at each site.
378 Caucasian PI ZZ subjects in 167 families were enrolled in the AAT Genetic Modifier Study. At least one PI ZZ sibling pair was necessary for a family to be eligible, with both siblings at least 30 years of age. All participants provided written informed consent. The study protocol included a questionnaire, spirometry and a blood sample for DNA and alpha 1-antitrypsin studies.
Ascertainment scheme and proband designation
Ascertainment of eligible sibling pairs was based upon confirmed homozygosity for the Z allele at the SERPINA1 locus (PI ZZ). The index case was the first person in the family diagnosed with AAT deficiency (irrespective of liver or lung disease), based upon questionnaire responses. Each family only had one index case; all other ZZ family members were classified as non-index. Due to death or non-participation of some index cases, index cases were not available for 27 families.
Questionnaire
Each participant completed a computer-based modified version of the ATS-DLD Epidemiology Questionnaire 7 . The specific questions for defining the presence or absence of chronic bronchitis, wheezing, asthma and pneumonia are summarized in the online supplement. Pack-years of cigarette smoking were calculated by multiplying the number of years smoked times the average number of daily cigarettes smoked, divided by 20. 'Ever smokers' answered affirmative to the question 'Have you ever smoked cigarettes'; no was defined as less than 20 packs of cigarettes or 12 oz of tobacco in a lifetime or less than a cigarette a day for 1 year. 'Current smokers' answered negative to 'Have you stopped smoking (as of one month ago).' Spirometry A full description of the spirometry methods is provided in the online supplement. Pre-and post-bronchodilator spirometry testing was performed according to American Thoracic Society standards 8 with the Jaeger Masterscope PC Spirometer system (Jaeger, Hoechberg,Germany). For 16 subjects who had already undergone lung transplantation or lung volume reduction at the time of the study visit, spirometry that antedated the surgical procedure was obtained and the age used for analyses was the age at spirometry. Percent predicted values were calculated using predicted equations of Crapo and colleagues 9 . Unless indicated, data are presented for pre-bronchodilator FEV 1 . Bronchodilator reversibility was defined as the difference between absolute post-and pre-bronchodilator FEV 1 divided by baseline pre-bronchodilator FEV 1 .
Confirmation of AAT phenotype
Blood spot cards for alpha 1-antitrypsin studies were made from peripheral blood samples collected in EDTA. PI phenotyping was performed using the blood spot cards; specimens were assayed in polyacrylamide gels at pH 4.2-4.9 as previously described 10 . The phenotype results were reported only if two independent interpretations agreed. Genotyping was performed using the ARMS (Amplification and Refractory Mutation System) technology for the detection of point mutations 11 . A genotype of PI ZZ was assigned if the Z mutation was detected at position 342 and normal sequence was not detected.
Statistics
All computations were performed using the SAS statistical package (SAS Statistical Institute, Cary, North Carolina) on a SUN Microsystem. Chi-square and Student's t tests were used to compare counts and means respectively. The Mann-Whitney test was performed for non-normally distributed covariates. Covariates considered for inclusion in regression models included binary variables (asthma (yes=1, no=0), sex (male=1, female=0), ever-smoking status (yes=1, no=0), chronic bronchitis (yes=1, no=0), physician's diagnosis of asthma (yes=1, no=0), physician's diagnosis of pneumonia (yes=1, no=0), index case in family (yes=1, no=0)) and continuous variables (age, packyears of smoking). Multiple regression models were performed in SAS using the MIXED procedure in order to control for the correlation between family members.
RESULTS
The 378 confirmed PI ZZ individuals represented 372 siblings, 2 PI ZZ parents, 1 PI ZZ uncle and 3 adult children of PI ZZ individuals. Individuals were ascertained for the study on the basis of the PI ZZ genotype, and all genotypes were confirmed. There were also 50 parents (47 MZ, 1 SZ, 2 missing PI type) enrolled in these families who were not included in the epidemiological analysis. Characteristics of the PI ZZ individuals in this cohort are provided in Table 1 . Although 62% of this cohort reported a history of cigarette smoking, only 3% were current smokers. The mean pack-years of cigarette smoking were 18.2 for the smokers (median 17) and the majority started smoking during adolescence. Sixteen participants had undergone lung transplantation and/or lung volume reduction for the surgical management of emphysema. More than half of the participants reported a history of physician-diagnosed pneumonia, 37% reported physician-diagnosed asthma, and 22% met the criteria for chronic bronchitis.
For all PI ZZ participants, FEV 1 as a percent of predicted was graphed as a function of age and stratified by smoking history ( Figure 1 ). As expected, the mean FEV 1 was higher for non-smokers (non-smokers versus smokers p<0.0001). However, marked variability in FEV 1 values was noted, with some life-time non-smokers demonstrating airflow obstruction before age 50. 61% of the cohort met the criteria for GOLD Stage 2 or higher. We also examined the mean spirometric values and demographic features by index case designation (index or non-index). There was no significant difference between the percentage of men and women classified as an index or non-index subject (Table 1) . Index subjects had significantly lower spirometric measures and slightly higher pack-years of cigarette smoking than non-index subjects. There were more non-index subjects who were current smokers. Although there was no difference in the report of general lung problems before age 16, more index subjects reported a history of asthma before age 16. Although the number of individuals were small, asthma diagnosis prior to 16 was a significant predictor of airflow obstruction, with an odds ratio of 4.5 (95% 1.6-12.6, p=0.004), with 15 of the 20 individuals with asthma before age 16 having severe COPD. The mean FEV 1 for subjects with asthma before age 16 was 39.8% predicted (+ 24.9 % predicted). More index subjects reported a history of physician-diagnosed asthma and physician-diagnosed pneumonia but not chronic bronchitis symptoms (Table 1) .
Univariate and multivariate models were evaluated as predictors of FEV 1 (percent predicted) in all subjects, revealing that in addition to cigarette smoking and index case status, pneumonia, asthma, chronic bronchitis and male gender were associated with lower FEV 1 (Tables 2a, 2b ). Because spirometric prediction equations may not capture all of the variation in FEV 1 in AAT deficiency, we repeated the analyses using the percent predicted equations proposed by Hankinson et al 12 .
Using the Hankinson predicted equations, our results remained robust for the overall cohort and for the non-index subgroup; the effect estimates for sex were attenuated only for the index case subgroup analysis. We also evaluated bronchodilator reversibility in this cohort and observed that the mean bronchodilator responsiveness (measured as the percent change in the absolute lung function as a function of the baseline FEV 1 ) was 6.7%. As expected, bronchodilator responsiveness was associated with lower FEV 1 (p<0.0001). In univariate models, significant predictors of bronchodilator responsiveness included pneumonia (p=0.01), male sex (p=0.03), and pack-years of smoking (p=0.0008); there was a trend for physician-diagnosed asthma (p=0.06). In a multivariate model that included sex, packyears of smoking, asthma and pneumonia, only sex, pack-years of smoking and pneumonia remained significant predictors (p<0.05) Logistic regression analysis was performed to identify predictors of moderate to severe airflow obstruction in all subjects (Table 3a, 3b); these models for severe COPD demonstrated the same significant predictors as FEV 1 analyzed as a quantitative outcome. The odds for severe airflow obstruction in the overall cohort were highest for index cases, males, individuals with a history of cigarette smoking, and subjects with a history of asthma, chronic bronchitis, and/or pneumonia. , female=0) , pack-years of cigarettes, eversmoking (yes=1, no=0), asthma (yes=1, no=0), pneumonia (yes=1, no=0) , chronic bronchitis (yes=1, no=0), index case (yes=1, no=0) ** Estimate for pack-years is for each pack-year smoked Because being the index case in a family was a strong predictor of reduced FEV 1 and severe airflow obstruction, we parsed the group by index case status (index versus nonindex) and performed the same covariate modeling in the stratified cohort (Tables 2 and  3) . In multivariate analysis, smoking, sex, a history of asthma, and a history of pneumonia were predictors of severe airflow obstruction in both index and non-index individuals, but chronic bronchitis was a significant predictor of airflow obstruction only in non-index individuals (Table 3b) . Similar results were obtained for FEV 1 as a quantitative outcome (Table 2b) , although asthma was not significantly associated in index cases (p=0.08).
Subsequently, we investigated the characteristics of the 378 PI ZZ individuals stratified by sex, as sex was a highly significant predictor of both FEV 1 and severe airflow obstruction in univariate and multivariate models. The overall demographics for men and women are presented in Table 4 (and supplemental Tables 1 and 2 ). Although there was no difference in the percentage of men versus women who reported a history of cigarette smoking, on average men smoked a mean of 5.3 pack-years more and started smoking at a younger age. Overall, men had significantly lower values for FEV 1 (percent predicted) and FEV 1 /FVC (Table 4) ; this trend persisted even among the non-smokers , with men who were non-smokers having lower pre-and post bronchodilator spirometric measures than women (for pre-bronchodilator FEV 1 (72.2% predicted in men versus 86.3% predicted in women, p=0.003 )and for pre-bronchodilator FEV 1 /FVC (58.7 in men versus 69.2 in women, p=0.0006), with similar results for postbronchodilator spirometry with p<0.002 ). For all PI ZZ men and women, FEV 1 (percent predicted) was graphed separately for smokers and non-smokers as a function of age and stratified by sex (Figure 2a-smokers, Figure 2b -non-smokers), further demonstrating this marked variation in FEV 1 for women and men. We repeated the analyses using the percent predicted equations proposed by Hankinson et al 12 .
Our results remained robust regardless of the predicted models used. There were no differences between the percentages of men and women who reported "lung problems before age 16", wheezing, physician diagnosis of asthma or pneumonia, although there was a significant trend for men to report chronic bronchitis more frequently (p=0.05) (data not shown). The most marked contrast for mean FEV 1 was for those individuals reporting a history of asthma before age 16 (men-26.9% predicted, women-55.0% predicted , p=0.03).
We examined the predictors of airflow obstruction in non-index men and women to determine if there were sex differences in the predictors of severe airflow obstruction. Despite a similar sex distribution of men and women in the index and non-index group.bmj.com on April 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from categories, female index and non-index subjects had higher FEV 1 and FEV 1 /FVC values compared to men.
For the analysis of airflow obstruction, we focused on the non-index subjects. Only 15% of the female non-index subjects had severe airflow obstruction. The predictors of severe airflow obstruction were the same for male and female non-index subjects on univariate analysis; on multivariate analysis asthma and chronic bronchitis remained robust predictors of airflow obstruction only in men (Table 5a , 5b). History of pneumonia 4.14 (1.49-11.54) 3.51 (1.04-11.85) *Multivariate model includes sex (male=1), pack-years of cigarettes, ever-smoking (yes=1), asthma (yes=1), pneumonia (yes=1) , chronic bronchitis (yes=1), index case (yes=1) ** Estimate for pack-years is for each pack-year smoked
DISCUSSION
The development of COPD in the setting of severe alpha 1-antitrypsin (AAT) deficiency is highly variable. Host factors, such as modifier genes, likely interact with environmental factors to contribute to an individual's manifestations of lung disease. Many people are tested for AAT deficiency due to existing lung disease, and this ascertainment scheme biases observations of the natural history of lung function. Previous studies have raised concerns about the influence of ascertainment bias in studies designed to investigate determinants of lung disease in PI ZZ subjects. One important and unique feature of our cohort is that it represents the first large collection of sibling pairs and family members systematically enrolled in this study on the basis of homozygosity for the Z mutation of the SERPINA1 gene, irrespective of the presence of lung or liver disease. Evaluating the predictors of airflow obstruction in the non-index individuals in such families may provide insight into predictors of variable severity of COPD in alpha 1-antitrypsin deficient individuals.
Our study suggests that asthma, pneumonia, chronic bronchitis, and sex have the largest impact on the non-index subjects with alpha 1-antitrypsin deficiency, many of whom still have lung function in the normal range; asthma and chronic bronchitis are not significant predictors in the index individuals. When we focused on identifying risk factors for severe COPD, sex, smoking, pneumonia and chronic bronchitis all had odds ratios greater than 2, and these predictors could identify important pathways for genetic modifiers of COPD in AAT deficiency. A childhood history of asthma, although present in a small number of individuals in our study, was associated with the most severe COPD. Although the individual predictors that we investigated have been suggested as predictors of lung function in some prior studies of AAT deficient individuals, this observed difference in families for predictors of lung function between index and nonindex individuals, as well as men and women, provides insight into the variable susceptibility to COPD in AAT deficiency as well as familial discordance for COPD, despite similar smoking histories.
Cigarette smoking is the most important risk factor for the development of emphysema in AAT deficient individuals, but the variability and dose-response to this exposure suggest the importance of genetic and other environmental factors. Similar to other investigators [13] [14] [15] [16] [17] [18] , we have observed that smoking was often but not always associated with lower FEV 1 . Individuals with AAT deficiency who smoke often develop obstructive lung disease at an early age 16 14 13 , but we have corroborated that some current and former smokers have preserved lung function 4 . We also observed that sex, smoking and a history of pneumonia were important predictors of lung function in index and nonindex individuals. A physician diagnosis of asthma and chronic bronchitis contributed to severity of COPD in the non-index individuals. This observation in the non-index individuals, who tend to have higher FEV 1 , provides insight into the types of symptoms (cough, sputum, and wheeze) that may portend susceptibility to lung function decline and COPD amongst ZZ individuals. Further research will be required to determine whether the increased risk for airflow obstruction among individuals with symptoms of chronic cough and phlegm and episodes of pneumonia could relate to bronchiectasis, which is also associated with AAT deficiency 19 . Airway hyperresponsiveness and wheezing may be susceptibility phenotypes for worse lung outcomes, especially in the setting of cigarette smoking. In this cohort, 25% had at least a 10% increase in FEV 1 and this reversibility was associated with lower lung function. Although emphysema/COPD may be misdiagnosed as asthma in adults with alpha 1-antitrypsin deficiency 20 , a diagnosis of asthma in childhood is unlikely to be due to emphysema/COPD. In individuals in Sweden identified with AATD as part of neonatal screening, 15% were given a diagnosis of asthma by age 22 and 29% selfreported recurrent wheezing episodes 21 . We observed that a physician diagnosis of asthma before age 16 was strongly associated with reduced FEV 1 and severe COPD in adulthood, suggesting asthma (or the presence of asthma-like symptoms) may define a particularly susceptible subset of PI ZZ individuals. In our study, the most profound reduction in lung function was among men with a history of asthma before age 16, and a physician diagnosis of asthma remained an important predictor of airflow obstruction in non-index case males (not females), suggesting that one potential difference between men and women with COPD may be related to lung inflammation. Inflammation associated with asthma may portend the development of airflow obstruction in later life through limiting the level of maximally achieved lung function or through accelerating lung function decline. Prior studies have demonstrated an association between asthmatic features and COPD in adults with AAT deficiency 5, 6, 22 , and asthmatic symptoms in adults have been previously suggested as a risk factor for lower FEV 1 18 ,3 . Pneumonia was associated with lower FEV 1 and severe airflow obstruction in individuals with AAT deficiency in our study cohort, although it is unclear if pneumonia precedes or follows COPD. Although pneumonia has been suggested as a risk factor for COPD in the past, 4 this has not been a consistent observation 3, 15 . Interestingly, we observed that although a physician diagnosis of pneumonia was associated with lower lung function in both men and women, a report of pneumonia before age 16 was not, suggesting that pneumonia may be a consequence rather than a cause of COPD.
Sex has been reported as a risk factor for lower FEV 1 in some but not all prior studies of AAT deficient individuals. An increased risk for lung disease in males has been noted by various investigators (Tobin 1983 , Larsson 1978 , Piitulainen 1997 . No significant effect was observed by Silverman and colleagues 4 , but the small sample size in that study may have limited the ability to detect a gender effect. The higher number of males among identified PI Z individuals has been attributed to higher rates of smoking among males 18 ,23 but our current data and previous data in non-smokers 3 suggest that there are sex-based differences for susceptibility to lung disease in AAT deficiency additional to cigarette smoking. Males had lower spirometry measurements than females in our cohort, regardless of index case or smoking status, age, and/or a history of pneumonia, chronic bronchitis or asthma. Larsson and colleagues noted a low prevalence of COPD in nonsmoking women in their cohort 14 . Tobin and colleagues observed wide variability in lung function amongst PI Z non-smokers but also noted that older female non-smokers had less limitation of lung function than older males. They also noted that FEV 1 percent predicted was lower in men than women and that the effect of gender and smoking were significant upon multiple regression analysis, although there was no significance of a sexby-smoking interaction term 13 . Although we, like Tobin and colleagues, did not observe a significant interaction term for smoking and sex (results not shown), it may be more likely that the significant interaction will be modifier gene-by-sex factors. Other environmental exposures, such as occupational dust exposures, are also important to consider as potential modifiers of the risk for COPD in AAT deficiency. Piitulainen and colleagues observed that male non-smokers were at increased risk for low lung function when compared to female non-smokers 3 . In a sex-stratified analysis they observed that age was an independent predictor of FEV 1 in both men and women but "wheeziness" was a predictor only in men. In our study, men have lower spirometric measures than women, and amongst the non-index cases, symptoms of chronic bronchitis and a physician diagnosis of asthma were significant predictors of severe airflow obstruction only for men. Although this may be because of the lower number of non-index women with airflow obstruction, as noted above men with alpha 1-antitrypsin deficiency may have increased inflammation associated with asthma and chronic bronchitis symptoms.
There have been many previous studies of risk factors for reduced lung function in PI ZZ individuals, but our study has several unique features. First, only subjects with a confirmed PI ZZ genotype were considered; second, we used standardized spirometry with the same spirometry system across centers to minimize technical variability from the spirometric measures; third, we collected a large number of non-index cases and adjusted for potential familial correlations within the multivariate models. Limitations include a potential effect of recall bias for childhood asthma as well as physician's diagnosis of pneumonia and asthma. There is also the potential for misclassification bias associated with COPD diagnosed as asthma. We do not have corroborating data such as chest radiological studies, sputum assessments for pneumonia or methacholine testing for asthma. Ascertainment bias is also important to consider as a limitation, although focusing on the observations in the non-index subjects partially broaches this bias. Although a complete understanding of the natural history of lung disease in PI ZZ individuals will require enrolling subjects without ascertainment bias from a large general population sample, our current study confirms that (in addition to cigarette smoking) sex, asthma, chronic bronchitis, and possibly pneumonia are risk factors for reduced FEV 1 and severe airflow obstruction in PI ZZ individuals. These results suggest that amongst those with severe AAT deficiency, men, individuals with symptoms of chronic bronchitis, and/or a past diagnosis of asthma or pneumonia may benefit from closer monitoring and potentially earlier treatment.
Genetic modifiers are likely important in the variable development of COPD in individuals with severe alpha 1-antitrypsin deficiency. We have identified several determinants of COPD in a large collection of siblings homozygous at the PI ZZ risk locus. Using family-based genetic methods these epidemiological factors may identify important genetic modifiers (such as asthma genetic modifiers of COPD in PI ZZ individuals) and key interactions (such as gene-by-sex) that will provide new insights into the pathophysiology and natural history of lung disease in PI ZZ alpha 1-antitrypsin deficiency. consecutive months or more during the year" and "Do you bring up phlegm like this on most days for 3 consecutive months or more during the year" combined with a response that these symptoms of cough and phlegm had been present for 2 or more years.
Wheezing was defined as an affirmative answer to the question "Does your chest ever sound wheezing or whistling?" Asthma was defined by an affirmative answer to the questions "Have you ever had asthma?" and "Was it confirmed by a doctor?" Pneumonia was defined by an affirmative answer to the questions "Have you ever had pneumonia?"
and "Was it confirmed by a doctor?"
Spirometry
Spirometry testing was performed with the Jaeger Masterscope PC Spirometer system (Jaeger, Hoechberg,Germany). Standardized training of all research assistants was performed. For subjects who had already undergone lung transplantation or lung volume reduction at the time of the study visit, spirometry that antedated the surgical procedure was obtained. In these participants, the age used for analyses was the age at spirometry.
Pre-and post-bronchodilator study spirometry was performed according to American Thoracic Society standards. After pre-bronchodilator spirometry, two puffs of albuterol (180 mg) were provided through a spacer, followed by repeat spirometry to obtain postbronchodilator measures. We selected the highest FEV 1 value and the highest FVC from any effort to define pre and post-bronchodilator spirometric phenotypes. Percent predicted values were calculated using predicted equations of Crapo and colleagues (2) . 
